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Background: Transcutaneous supraorbital nerve stimulation (tSNS) with the Cefaly® device was recently found
superior to sham stimulation for episodic migraine prevention in a randomized trial. Its safety and efficiency in
larger cohorts of headache sufferers in the general population remain to be determined.
The objective of this study was to assess the satisfaction with the Cefaly® device in 2,313 headache sufferers who
rented the device for a 40-day trial period via Internet.
Methods: Only subjects using specific anti-migraine drugs, and thus most likely suffering from migraine, were
included in the survey. Adverse events (AEs) and willingness to continue tSNS were monitored via phone interviews
after the trial period. A built-in software allowed monitoring the total duration of use and hence compliance in
subjects who returned the device to the manufacturer after the trial period.
Results: After a testing period of 58.2 days on average, 46.6% of the 2,313 renters were not satisfied and returned
the device, but the compliance check showed that they used it only for 48.6% of the recommended time. The
remaining 54.4% of subjects were satisfied with the tSNS treatment and willing to purchase the device. Ninety-nine
subjects out of the 2,313 (4.3%) reported one or more AEs, but none of them was serious. The most frequent AEs
were local pain/intolerance to paresthesia (47 subjects, i.e. 2.03%), arousal changes (mostly sleepiness/fatigue,
sometimes insomnia, 19 subjects, i.e. 0.82%), headache after the stimulation (12 subjects, i.e. 0.52%). A transient local
skin allergy was seen in 2 subjects, i.e. 0.09%.
Conclusions: This survey of 2,313 headache sufferers in the general population confirms that tSNS with is a safe
and well-tolerated treatment for migraine headaches that provides satisfaction to a majority of patients who tested
it for 40 days. Only 4.3% of subjects reported AEs, all of them were minor and fully reversible.
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Figure 1 Area covered by the tSNS electrode.
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Transcutaneous supraorbital neurostimulation with the
Cefaly® device is a safe and satisfactory treatment modal-
ity for migraine headache sufferers in the general popu-
lation who tested it for 40 days. Treatment failure may
be partly due to poor compliance.
Background
Migraine is a highly prevalent primary headache dis-
order and one of the most disabling diseases worldwide
according to the recent epidemiologic data [1]. Prevent-
ive anti-migraine drug therapies have incomplete effi-
cacy and many of them have cumbersome side effects
[2]. Blumenfeld et al. (2013) [3] have recently found that
only 28.3% and 44.8% of subjects suffering respectively
from the episodic and chronic forms of migraine (ICHD-
III beta criteria 1.1, 1.2 and 1.3 [4]) were currently using a
preventive medication [3]. The reasons for treatment dis-
continuation were lack of efficacy and side effects in an
equal proportion. Furthermore, over the last decade hardly
any novel migraine preventive drug has been marketed.
Hence, there is a need for new preventive therapies with
similar or better clinical efficacy, and most importantly
fewer treatment-related side effects.
Peripheral nerve stimulation (PNS) has shown promis-
ing preventive properties in episodic and chronic migraine
[5]. PNS conveys its effects by the electrical stimulation of
peripheral nerves branches either sub- or percutaneously
with implantable devices, or transcutaneously via superfi-
cial skin electrodes linked to external neurostimulators.
Due to its invasiveness percutaneous PNS like occipital
nerve stimulation (ONS) was used hitherto only in the
most disabled migraine patients [5-7]. Transcutaneous
PNS have the advantage of being non-invasive and thus
applicable also in less severely disabled subjects suffering
from episodic migraine.
We have shown previously in a randomized double-blind
sham-controlled trial that transcutaneous supraorbital neu-
rostimulation (tSNS) is effective in the preventive treat-
ment of episodic migraine (the PREMICE trial, [8]). In this
study, subjects were treated with an external ultra-portable
and user-friendly tSNS device stimulating both supra-
orbital nerves, the Cefaly® device (CEFALY Technology,
Herstal, Belgium). After daily 20 minutes tSNS sessions
for 3 months, the 50% responder rate was 38.2% for ac-
tive tSNS vs.12.1% for sham stimulation [8]. The effect
was significant, and within the range of other migraine
preventive therapies. Moreover, there were no side ef-
fects or drop-outs due to device-related adverse events.
However, the number of subjects included in this trial
was limited to 67 patients recruited in tertiary headache
clinics. It remains therefore to be studied how tSNS with
the Cefaly® device performs in larger cohorts of headache
sufferers in the general population. For this purpose, wehave conducted a survey of subjects who rented the device
via Internet for 40 days, in order to assess safety and satis-




A prospective registry of 2,573 headache sufferers who
rented the tSNS Cefaly® device (CEFALY-Technology,
Liège, Belgium) was established between September 2009
and June 2012. Most subjects were French or Belgian citi-
zens, while a minority lived in Switzerland, three countries
where subjects can directly rent and buy the device via the
Internet without medical prescription. The device can be
rented at a cost of 49€ for 40 days, where after the patient
has to decide either to return the device or to keep it and
pay the balance between its cost of 295€ and the rental fee.
Transcutaneous supraorbital neurostimulation
tSNS was delivered with an external self adhesive elec-
trode placed on the forehead (Figure 1, Cefaly® device,
CEFALY Technology, Liège, Belgium). The bipolar elec-
trode (30 mm × 94 mm) covers bilaterally the origins of
the supraorbital nerves (branches of 1st trigeminal
Magis et al. The Journal of Headache and Pain 2013, 14:95 Page 3 of 8
http://www.thejournalofheadacheandpain.com/content/14/1/95division). A constant current generator (maximum skin
impedance of 2.2 KΩ) generates biphasic rectangular
impulses with an electrical mean equal to zero (pre-
ventive stimulation protocol: impulse width 250 μS, fre-
quency 60 Hz, maximum intensity 16 mA). All subjects
received an explicative leaflet advising to perform tSNS
at least once daily in order to obtain a preventive anti-
migraine effect. As single sessions have a fixed duration
of 20 minutes, the recommended minimal total time of
use was 800 minutes in subjects renting the device for
40 days. A built-in electronic system allowed recording
of the total time of tSNS use in subjects who returned
then device to the manufacturer after the trial period.
Data collection and processing
The objectives of this survey were to record self-reported
adverse events and to assess the satisfaction of subjects
who received the tSNS Cefaly® device at home with its ac-
cessories for the rental period.
After the end of this rental period they were contacted
to answer to the following questions:
1. Which kind of medication do you usually take to
treat your headache attack?
2. Did you have side effects when using tSNS or any
complaint or comment about the device?
3. Did you encounter technical issues with the device?
4. Are you satisfied with tSNS and do you want
continue the treatment?
“Satisfied” subjects who wanted to keep on the treat-
ment had to purchase the device (i.e. to pay 246€),
whereas “unsatisfied” subjects sent it back by surface
mail.
The devices collected from unsatisfied subjects were
analyzed for the total time of tSNS use in order to esti-
mate compliance.
A trained medical secretary was paid by the manufac-
turer to contact all subjects by phone or e-mail after the
rental period. Phone contact was tried in the morning,
at noon and in the afternoon; an e-mail was sent in case
the person did not answer the phone. This was repeated
for up to 2 weeks until a formal contact was achieved.
A total of 2,573 patients rented the device during the
29 months of the survey; 26 never responded to the
phone calls or e-mails; 234 were not using triptans and
were not included in the survey, as they were assumed
not to suffer from migraine. In the three involved coun-
tries (Belgium, France and Switzerland) triptans are in-
deed only delivered and/or reimbursed with a medical
prescription certifying that the patient has a diagnosis of
migraine according to ICHD-II criteria [9].
The diagram in Figure 2 depicts the sequential steps of
the survey.According to European regulations on non-interventional
studies with medical devices (CE directive 93/42 and
ISO 13485) this survey did not require ethics committee
approval.
Results
According to the triptan use selection criterion, 2,313 head-
ache sufferers were included in the survey (age 14–87 years,
1641 females i.e. 70.95% and 672 males i.e. 29.05%): 1,208
(52.2%) from France, 999 (43.2%) from Belgium and 106
(4.6%) from Switzerland. The average rental period, com-
puted from the day they received the device until they were
actually contacted to answer the questions, was 58.2 ±
33.6 days.
Safety
Ninety-nine subjects reported at least one adverse event
(AE) during tSNS therapy, i.e. 4.3% of all subjects. In the
subgroup of unsatisfied patients the AEs rate was 5.48%
(59 patients) and it was 3.24% (40 patients) in the sub-
group of satisfied patients. Five patients reported more
than one AE, one in the satisfied subgroup and four in
the unsatisfied subgroup. Forty-six subjects, i.e. 2%,
stopped tSNS because of an AE. None was serious and
all were fully reversible. The most remarkable AE was a
forehead skin allergy in 2 subjects (0.09%).
Table 1 is an exhaustive list of all AEs recorded.
The most frequent AE was intolerance to the paresthesia
induced by the electrical stimulation (N= 31, 46% of all
AEs), despite the fact that the subjects were allowed to
interrupt the gradual intensity increase from 0 to 16 mA
by pressing the “on” button as soon as the forehead sensa-
tion became uncomfortable. All subjects complaining of
paresthesia intolerance stopped the treatment. Some other
painful feelings were reported: 3 strong pressure feelings
on the forehead, 2 dental and 2 cervical pains during the
session. Two subjects felt paresthesia more on one side of
the forehead. While the paresthesia stopped in most sub-
jects at the end of the stimulation, 4 individuals reported
that the forehead paresthesia persisted for several hours
after the end of the stimulation.
Twelve subjects (0.52%) complained after the tSNS
session of tension-type like headache that led to treat-
ment interruption.
Arousal and sleep changes were the second most fre-
quently reported AEs (19 subjects or 18.6% of all AEs).
Among them, sleepiness during the stimulation was re-
ported by 12 subjects, while 4 complained of insomnia.
Three subjects (3.03%) complained of a feeling of stress
during the tSNS session.
Three subjects had nausea and vomiting at the end of
a session, but did not complain of headache.
Two subjects reported not being able to keep their eyes
open during the stimulation. Two reported increased
n=2,573
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Figure 2 Study flow chart.
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Table 1 AE reported by the patients within the trial period
Number of patients Percentage of AE Percentage of patients
Do not like the feeling and do not want to continue using the device 29 29.29% 1.25%
Sleepiness during the Cefaly® session 12 12.12% 0.52%
Headache after a Cefaly® session 12 12.12% 0.52%
Reversible forehead skin irritation 5 5.05% 0.22%
Insomnia 4 4.04% 0.17%
Feeling of fatigue 3 3.03% 0.13%
Persistent forehead paresthesia for several minutes after the session 3 3.03% 0.13%
Feeling of stress during the session 3 3.03% 0.09%
Allergic skin reaction 2 2.02% 0.09%
Dental pain during the session or at the beginning 2 2.02% 0.09%
Inability to keep eyes open during sessions 2 2.02% 0.09%
Feeling of contusion on the forehead during a few days 2 2.02% 0.09%
Pre-existing tinnitus increased during the session 1 1.01% 0.04%
Tinnitus appearing during some sessions 1 1.01% 0.04%
Red eye after a session 1 1.01% 0.04%
Eyes weeping during a session 1 1.01% 0.04%
Wake up during night with a feeling of anxiety and tremor 1 1.01% 0.04%
Vertigo during the first session 1 1.01% 0.04%
Vomiting after a session 1 1.01% 0.04%
Forehead skin burning sensation during a session 1 1.01% 0.04%
Cervical pain during sessions 1 1.01% 0.04%
Cervical pain with nausea after the two first sessions 1 1.01% 0.04%
Short feeling of electrical shock 1 1.01% 0.04%
Slight pain at one eyebrow during the first session 1 1.01% 0.04%
Nausea and vertigo during sessions 1 1.01% 0.04%
Nausea during sessions 1 1.01% 0.04%
More head pain when using the device during a headache 1 1.01% 0.04%
Forehead and cranial anaesthesia feeling during a few hours after a session 1 1.01% 0.04%
Pressure feeling between the eyebrows during sessions 1 1.01% 0.04%
Numbness at the back of the head after a session 1 1.01% 0.04%
Stronger paresthesia feeling on the left side 1 1.01% 0.04%
Stronger paresthesia feeling on the right side 1 1.01% 0.04%
Subjective tachycardia during a session 1 1.01% 0.04%
Migraine feeling during sessions 1 1.01% 0.04%
Complaints reported by patients.
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one tearing.
Five subjects (5%) complained about transient skin ir-
ritation and 2 subjects had a local cutaneous reaction,
probably allergic to the electrode gel containing acrylate
(2% of all AEs, and 0.09% of all subjects) (Figure 3).
These patients did not report a history of allergy to ad-
hesive tapes but one of them had previously suffered
from an allergic skin reaction.The four remaining AEs were single and mild: numb-
ness at the back of the head, slight pain over one eye-
brow, feeling of abrupt electrical variation, tachycardia
during one session.
Satisfaction
Out of 2,313 subjects, 1,236 (53.4%) were satisfied with
the tSNS therapy and wanted to continue the treatment.
These subjects purchased the Cefaly® device. On the
Figure 3 Allergic skin reaction.
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tSNS and sent back the device.
Compliance
The devices collected back from the 1,077 non-satisfied
subjects who discontinued the therapy were analyzed for
time of use (Table 2). A built-in electronic system in each
device recorded the total time of use. In these 1,077 unsat-
isfied subjects the mean time of use was 583 ± 903 mi-
nutes, for an average rental period of 49.5 ± 26.7 days. As
the recommended treatment schedule was one session of
20 minutes per day, their time of use was 58.8% of the rec-
ommended time.
Interestingly, 4.46% of “unsatisfied” subjects (N = 48,
2.08% of all subjects) did not even switch on the device,
and 19.03% used it less than 60 minutes. Conversely,
40% of the discontinuers applied the tSNS for more than
400 minutes over the rental period (N = 431, 18.63% of
all subjects), which was probably sufficient to achieve a
therapeutic effect. If we exclude from the survey subjects
who never switched on the device, i.e. who did not try
the treatment at all, the percentage of satisfied subjects
raises to 55.51%. Also, if one accepts that 400 minutes of
treatment are necessary to obtain a treatment effect,
only 18.63% of all subjects would be classified as non-Table 2 Compliance in the 1,077 unsatisfied subjects
Total time of use (minutes) Number of subjects (percentage)*
0 48 (4,46%)
1 to 20 58 (5,39%)
21 to 40 46 (4,27%)
41 to 60 53 (4,92%)
60 to 100 78 (7,24%)
100 to 200 174 (16,16%)
200 to 400 189 (17,55%)
> 400 431 (40.02%)
*Number (and percentage) of unsatisfied subjects who used the device for the
time indicated in the first column i.e. 48 “unsatisfied” subjects did not switch
on the device, 58 used the device between 1 and 20 minutes, 46 between 21
and 40 minutes, etc.responders; the compliance of the other discontinuers
(N = 646) was not large enough to assess a treatment
response.
Out of the 646 patients who used their device less than
400 minutes 56 reported AEs (8.64%), i.e. twice more the
AE rate for all subjects. In patients who used the device at
least 400 minutes the AE rate was 1.85%.
Discussion
This survey on a large cohort of 2,313 headache suf-
ferers in the general population provides important data
on tolerance and safety of tSNS with the Cefaly® device
as well as some information about its performance.
First, it underscores the safety of tSNS and the low in-
cidence of self-reported AEs (4.3% of 2,313 subjects).
About half (2%) of these subjects discontinued the ther-
apy because of an AE. In the PREMICE trial [8] the 34
subjects randomized to the effective tSNS (verum) arm
reported no AE and none dropped out, which can be ex-
plained by the small number of patients. In the present
survey the most frequent adverse effect was intolerance
to forehead paresthesia that was perceived as painful
burning sensations. As a matter of fact, paresthesia is a
“normal” sensation linked to every PNS, and responsible
for the difficulty in effectively blinding such studies. It is
common experience, however, that a number of subjects
in the general population do not tolerate the sensations
induced by cutaneous electrical stimuli even at low inten-
sities. This intolerance may be pronounced in migraine
sufferers and might be related to the cutaneous allodynia
that may persist in some of them between attacks [5]. Sub-
jects reporting sleepiness confirm that tSNS can have seda-
tive properties, as shown previously in a study of healthy
volunteers [10]. Finally, the most remarkable and cumber-
some AE was skin allergy under the forehead electrode
(0.09%). Though very rare, such an allergic reaction is well
known for self-adhesive electrodes and attributed to the
acrylate component of the electrode gel [11]. It is fully re-
versible within 10 days after removing the electrode and
can be avoided by using a newly developed hypoallergenic
gel without acrylate.
Second, this survey indicates that 53.4% of subjects
were satisfied with the tSNS after a trial period of on
average 58 days, and decided to continue the treatment
and to purchase the device. Although this is a purely
subjective global assessment, patients’ satisfaction could
somehow parallel treatment effectiveness. In the PRE-
MICE trial, 70.6% of episodic migraineurs were satisfied
with the treatment (29.4% very, 41.2% moderately satis-
fied) [8]. The global rate of satisfaction is lower in the
present survey, but one has to take into account that
subjects had to pay 246€, i.e. the difference between the
full price and the rental cost, to purchase the Cefaly® to
keep the device for treatment continuation, and that the
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pliance to tSNS therapy was 58.8% in subjects who dis-
continued the treatment while in the PREMICE study it
was 61.7% in the total group of patients. This slight dif-
ference can be due to the fact that only the devices of
unsatisfied subjects could be analyzed for time of use.
Moreover, patients included in the PREMICE trial were
recruited by established headache specialists and thus
well educated in headache management including the
use of headache diaries while the majority of subjects in-
cluded in the present survey had no regular neurological
follow-up.
If we exclude from the analysis those 48 unsatisfied
subjects who never used the device, the rate of satisfied
subjects raises to 55.5%. It is likely that non-satisfied
subjects who used the device for less than 400 minutes
(N = 646, 27.9% of the 2,313 subjects and 59.98% of the
unsatisfied subjects) were not sufficiently dosed to expect
a therapeutic effect, although they may have experienced
adverse effects. Conversely, those 40% of unsatisfied sub-
jects (18.6% of the 2,313 subjects) who applied tSNS for
more than 400 minutes, i.e. for a potentially effective dur-
ation, are most probably genuine non-responders.
The survey presented here has several weaknesses. The
major one is that we have no certainty about the precise
diagnosis of included subjects, which is the reason why we
have focused our analysis on safety and tolerance. We
assume that a majority of them probably suffered from
migraine because they were using triptans for the treat-
ment of headache attacks. In the three involved countries
(Belgium, France and Switzerland) triptans are not avail-
able over-the counter, but delivered and reimbursed only
with a medical prescription certifying that the patient suf-
fers from migraine according to ICHD-II criteria [9]. Trip-
tan users are thus most likely to have been diagnosed as
migraineurs by a general practitioner and/or a neurologist.
Whether they suffer from episodic or chronic migraine,
from migraine with or without aura cannot be determined
in our survey. Possible diagnostic confounders are mis-
diagnosed headache, tension-type headache, medication
overuse headache and cluster headache.
Other weaknesses are the absent control for concur-
rent drug treatment and for natural history of the head-
ache disorder, as well as the outcome parameter and the
time point at which it was assessed. As mentioned above,
patients’ satisfaction, the only parameter available here, is a
composite subjective outcome measure combining efficacy,
tolerance, adverse effects, expectations and, in this case,
willingness to pay. It is not a recommended primary meas-
ure of efficacy, like the number of headache days, and it
does not necessarily parallel a reduction in headache fre-
quency. Despite its shortcomings, however, patients’ satis-
faction is considered to be valuable in pragmatic trials such
as ours, according to the IHS guidelines for controlledtrials of drugs in migraine [12]. The time point of about
60 days of tSNS at which the subjects’ satisfaction was
assessed may not be optimal. In the PREMICE trial the
treatment period was 3 months and the reduction in mi-
graine day frequency was maximal at the end of the 3rd
month [8]. The tSNS efficiency may thus be underesti-
mated in our survey, though this would probably concern
only a minority of subjects, since the therapeutic advantage
over sham stimulation was already significant at the end of
the 2nd month of treatment in the PREMICE trial [8].
Finally, we cannot exclude the possibility that some indi-
viduals in whom the device was effective did not purchase
it for financial reasons, which would have led to an over-
estimation of the proportion of non-satisfied subjects.
Because of these shortcomings no definitive conclu-
sion about therapeutic efficacy can be drawn from this
survey.
Conclusions
This survey of 2,313 headache subjects treated with tSNS
is to the best of our knowledge the largest database avail-
able for a neuromodulation treatment in headache. Its
major contribution is to confirm the safety and excellent
tolerance of tSNS therapy with the Cefaly® device. Adverse
events were reported by only 4.3% of subjects and they
were all minor and reversible. The most frequent AE was
intolerance to the local paresthesia, which is a common,
though rare, reason for treatment interruption in every
PNS therapy. About 2% of subjects stopped the tSNS ther-
apy because of an AE, which is remarkably low compared
to preventive anti-migraine drugs [3]. Although this sur-
vey does not allow reliable deductions about efficacy for
methodological reasons, it provides some clinically useful
indications about patients’ satisfaction and compliance.
Among the 2,313 subjects, 53.4% were satisfied with the
treatment and the device, and decided to buy it. The mean
time of tSNS use in those subjects who discontinued the
therapy was 58.8% of the recommended time; 4.46% of
“unsatisfied” subjects did not even switch on the device,
and 19.03% used it for less than 60 minutes. Hence, low
compliance to tSNS is an issue that might explain lack of
efficacy in a number of subjects.
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